波立维联合低分子肝素钙治疗进展性脑梗死的疗效以及安全性评价

The efficacy and safety evaluation of plavix combined with low molecular weight heparin Calcium in the treatment of progressive cerebral infarction

目的观察波立维联合低分子肝素钙治疗进展性脑梗死的疗效,并评价其安全性。方法将89例进展性脑梗死患者随机分为观察组45例和对照组44例。观察组采用波立维联合低分子肝素钙治疗,对照组采用低分子肝素钙治疗。比较2组临床疗效,血小板聚集率、纤维蛋白原、全血黏度的变化,以及治疗后第3、7、14天时神经功能缺损程度评分(NDS),同时观察不良事件发生情况。结果观察组显效率及有效率分别为84.44%、97.78%,高于对照组的61.36%、86.36%;血小板聚集率、纤维蛋白原含量、全血黏度低于对照组;治疗后第7、14天时NDS评分低于对照组,差异均有统计学意义(P<0.05)。但2组在安全性方面无明显差异。结论波立维联合低分子肝素钙治疗进展性脑梗死疗效确切,并且安全性较好,值得临床推荐使用。

Objective To observe the efficacy of plavix and low molecular weight heparin Caleiurn in the treatment of progressive cerebral infarction, and evaluation the safety of it. Methods 89 eases of patients with progressive cerebral infarction were divided into observation group （45 cases） and control group （44 eases）. The observation group was treated with Plavix combined with low molecular weight heparin Calcium,while the control group were treatde with low molecular weight heparin Calcium only. The clinical effieieney, platelet aggregation rate, fibrinogen, whole blood viscosity changes, neurologic impairment seore（NIS） 3,7,14 days after treatment and adverse reactions of 2 groups were observed and compared. Results The significant efficiency （84.44%） and overall efficiency （97.78%） of observation group was significantly higher than those of the control group （61.36% ,86.36% ） ;while the observation group＇s platelet aggregation rate,fibrinogen content,whole blood viscosity were lower than that of the control group; the NIS 7,14 days after treatment of observation group was significantly low- er than that of the control group, the differences of above data were statistically significant （P 〈 0.05 ）. But there was no signifi- cant differenee in terms of safety between 2 groups. Conclusion The efficacy of plavix combined with low molecular heparin in the treatment of cerebral infarction was exactly, and with better security, which is worth clinical popularizing and applieation.